Market Overview

13 Emerging Biotechs With Catalysts In 2017

Share:
13 Emerging Biotechs With Catalysts In 2017
Related AIMT
35 Biggest Movers From Yesterday
Benzinga's Option Alert Recap From October 23
Aimmune Therapeutics (AIMT) Presents At Jefferies 2017 London Healthcare Conference - Slideshow (Seeking Alpha)
Related BMRN
9 Notable Biotechs Presenting At This Year's ASH Meeting
Benzinga's Top Upgrades, Downgrades For August 17, 2017
Investor Expectations to Drive Momentum within Meritor, Bloomin' Brands, LaSalle Hotel ... (GuruFocus)

Biotech stocks, which had a torrid 2016, can look ahead to the unfolding year with some hope, although given the quirky nature of the clinical trial outcomes, a recovery is still in question.

Wedbush has compiled a list of 13 emerging biotech stocks with catalysts in 2017.

1. Aimmune Therapeutics Inc (NASDAQ: AIMT)

Catalysts

  • Initiates RAMSES trial – Q117
  • Last patient completes up-dosing in AR101 PALISADE trial – H117, with 70:30 probability and 0-15 percent stock upside or downside potential
  • Pivotal Ph3 AR101 results from PALISADE trial – Q417, with 75:25 probability and 25-40 percent stock upside or downside potential

The firm reiterated its Outperform rating and $42 price target on Aimmune, which is a developer of treatments for food allergies.

2. Ascendant Resources Inc (CVE:ASND)

Catalysts

  • Enrollment update for pivotal trial for TransCon hGH – H117, with 50:50 probability and 0-5 percent stock upside or downside potential
  • Preclinical data for TransCon CNP – Q117, with 50:50 probability and 0-5 stock percent upside or downside potential
  • Submit IND for TransCon PTH / hypoparathyroidism – Q217
  • Submit IND for TransCon CNP / achondroplasia – Q417
  • Potential announcement of U.S./ex-U.S. partnership for TC hGH – 2017, with 50:50 probability and 0-25 percent stock upside potential

Wedbush has an Outperform rating and a $31 price target on Ascendis.

3. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)

Catalysts

  • Submit BLA for Pegvaliase / PKU – Q117, with 70:30 probability and 0-10 percent stock upside or downside potential
  • Full Ph1/2 results: BMN 270 FVIII/Hemophilia A gene therapy – Early January, with 60:40 probability and 0-15 percent stock upside or downside potential
  • Advisory committee meeting for Brineura – Q117, with 60:40 probability and 0-10 percent stock upside or downside potential
  • PDUFA date for Brineura (Cerliponase alfa) in CLN2 – April 27, with 65:35 probability and 0-10 percent stock upside or downside potential

The firm has a Neutral rating and a $102 price target on BioMarin.

4. Catabasis Pharmaceuticals Inc (NASDAQ: CATB)

Catalysts

  • Part B results Phase 1/2 CAT-1004 in DMD—12wk efficacy – Q117, with 50:50 probability and 5-25 percent stock upside or downside potential
  • Data from the Phase 2a trial of CAT-2054 at medical mtg – 2017
  • Initiate Phase 1 trial of CAT-4001 (safety, PK, PD) for ALS and FA – 2017

Webush has an Outperform rating and $46 price target for Catabasis.

5. Cohen & Steers Clsd-End Optuny Fnd, Inc. (NYSE: FOF)

Catalysts

  • Initiate Ph3 of SCS-Zuprata in ME-RVO (CLS-1003) – H117
  • Pivotal Ph3 data for SCS-Zuprata in ME-NIU (CLS-1001) – Q417/Q118, with 60:40 probability and 10-40 percent stock upside or downside potential
  • Potential Phase 1/2 data release for SCS-Zuprata in DME – H217, with 60:40 probability and 0-10 percent stock upside or downside potential
  • Ph1/ 2 data for CLS-1002 in wet AMD – 2017, with 50:50 probability and 0-40 percent stock upside or downside potential

Webush has an Outperform rating and $28 price target on Clearside Biomedical.

6. Intercept Pharmaceuticals Inc (NASDAQ: ICPT)

Catalysts

  • INT-767 Phase 1 results – Q117, with 50:50 probability and 0-10 percent stock upside or downside potential
  • Complete enrollment of Phase 3 REGENERATE trial, with 80:20 probability and 0-10 percent stock upside or downside potential
  • Data from Phase 2 CONTROL(OCA w/ stain in NASH) trial, with 80:20 probability and 5-20 percent stock upside or downside potential
  • Data from Phase 2 AESOP (PSC) trial, with 80:20 probability and 5-10 percent stock upside or downside potential

The firm has an Outperform rating and $224 price target for Intercept Pharma.

7. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)

Catalysts

  • Early indication that FDA may consider reviewing T1D – Q117, with 50:50 probability and 0-100 percent stock upside or downside potential
  • FDA PDUFA date for telotristat ethyl – February 28, with 90:10 probability and 0-15 percent stock upside or downside potential
  • Potential U.S. launch of telotristat ethyl – Q217, with 90:10 probability and 0-10 percent stock upside or downside potential
  • Potential EU approval of telotristat ethyl – 2017, with 80:20 probability and 0-10 percent stock upside or downside potential

Webush has an Outperform rating and $33 price target on shares of Lexicon.

8. Omeros Corporation (NASDAQ: OMER)

Catalysts

  • Additional data from Phase 2 trial of OMS721/aHUS/TMAs – 2017, with 75:25 probability and 0-10 percent stock upside or downside potential
  • OMS721 data in aHUS at ISN Word Congress of Nephology – April
  • OMS721 data in Renal Diseases at ERA-EDTA (Spain) – June 3-6

Wedbush has an Outperform rating and $47 price target for shares of Omeros.

9. Pacira Pharmaceuticals Inc (NASDAQ: PCRX)

Catalysts

  • Symphony Health EXPAREL estimate for December/Q4:16 – January 25
  • Potential regional exUS EXPAREL partnership(s) – 2017, with 90:10 probability and 10-20 percent stock upside or downside potential
  • IR-RCT¥ EXPAREL knee active comparator trial data release – Q117, with 60-40 probability and 10-20 percent stock upside or downside potential
  • Data release from two Ph3 Nerve Block Trials – Q117, with 80-20 probability and 10-40 percent stock upside or downside potential

The firm has an Outperform rating and $89 price target on Pacira Pharma.

10. Regulus Therapeutics Inc (NASDAQ: RGLS)

Catalysts

  • Potential removal of FDA clinical hold on RG-101 – Q117, with 60:40 probability and 5-40 percent stock upside or downside potential
  • Results from Phase 2 RG-101/GSK-175 trial – Q117, , with 50:50 probability and 0-15 percent stock upside or downside potential
  • Results from MAD study for RG-012 in HV – H117, with 50:50 probability and 0-5 percent stock upside or downside potential
  • Phase 2 HERA study in Alport resumes – H217

Wedbush has an Outperform rating and $13 price target for Regulus.

11. Sangamo Biosciences, Inc. (NASDAQ: SGMO)

Catalysts

  • Updated data from SB-728-1101 Cohort 3 HIV study – 2017
  • Data from Phase 1 SB-728-mR-HSPC HIV program – 2017
  • Preliminary data from SB-FIX / Hemophilia B & SB AAV-FVIII – 2017/H118, with 50:50 probability and 20-15 percent stock upside potential or 15-20 percent downside potential

Wedbush has a Neutral rating and $4 price target on Sangamo.

12. United Therapeutics Corporation (NASDAQ: UTHR)

Catalysts

  • Potential US sNDA approval for RemoSync (possibly April) – 2017, with 50:50 probability and 10-25 percent stock upside or downside potential
  • Launch of RemoSync (Remodulin implantable pump) – 2017, with 50:50 probability and 0-10 percent stock upside or downside potential
  • Initiate Phase 2/3 trial of eNOS gene therapy – 2017
  • FREEDOM-EV potentially completes enrollment – 2017, with 75:25 probability and 0-10 percent stock upside or downside potential

The firm has an Outperform rating and $229 price target on United Therapeutics.

13. XOMA Corporation (NASDAQ: XOMA)

Catalysts

  • Milestone payment to Xoma for $10 million – Q117; with 50:50 probability and a 0-10 percent stock upside or downside potential
  • Out licensing of IL-2 mAb program for immuno-oncology – Q117, ; with 50:50 probability and a 0-10 percent stock upside or downside potential
  • Updated data from Ph2 for XOMA 358 in CHI and PBS – H117, with 50:50 probability and a 0-15 percent stock upside potential or 0-10 percent downside potential
  • Initiation of a multi-dose trial of XOMA 358 in CHI – 2017

Wedbush rates XOMA Neutral, with a $14 price target.

Latest Ratings for AIMT

DateFirmActionFromTo
Oct 2017Credit SuisseMaintainsOutperform
Mar 2016Credit SuisseMaintainsOutperform
Mar 2016WedbushInitiates Coverage onOutperform

View More Analyst Ratings for AIMT
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Biotech Top Stories Analyst Ratings General Best of Benzinga

 

Related Articles (BMRN + AIMT)

View Comments and Join the Discussion!

Partner Center